278 related articles for article (PubMed ID: 21908426)
1. Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A.
Zhang Y; Conti MA; Malide D; Dong F; Wang A; Shmist YA; Liu C; Zerfas P; Daniels MP; Chan CC; Kozin E; Kachar B; Kelley MJ; Kopp JB; Adelstein RS
Blood; 2012 Jan; 119(1):238-50. PubMed ID: 21908426
[TBL] [Abstract][Full Text] [Related]
2. Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease.
Pal K; Nowak R; Billington N; Liu R; Ghosh A; Sellers JR; Fowler VM
Blood; 2020 May; 135(21):1887-1898. PubMed ID: 32315395
[TBL] [Abstract][Full Text] [Related]
3. Establishment of mouse model of MYH9 disorders: heterozygous R702C mutation provokes macrothrombocytopenia with leukocyte inclusion bodies, renal glomerulosclerosis and hearing disability.
Suzuki N; Kunishima S; Ikejiri M; Maruyama S; Sone M; Takagi A; Ikawa M; Okabe M; Kojima T; Saito H; Naoe T; Matsushita T
PLoS One; 2013; 8(8):e71187. PubMed ID: 23976996
[TBL] [Abstract][Full Text] [Related]
4. Mutations in non-muscle myosin 2A disrupt the actomyosin cytoskeleton in Sertoli cells and cause male infertility.
Sung DC; Ahmad M; Lerma Cervantes CB; Zhang Y; Adelstein RS; Ma X
Dev Biol; 2021 Feb; 470():49-61. PubMed ID: 33188738
[TBL] [Abstract][Full Text] [Related]
5. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation.
Pecci A; Malara A; Badalucco S; Bozzi V; Torti M; Balduini CL; Balduini A
Thromb Haemost; 2009 Jul; 102(1):90-6. PubMed ID: 19572073
[TBL] [Abstract][Full Text] [Related]
6. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.
Heath KE; Campos-Barros A; Toren A; Rozenfeld-Granot G; Carlsson LE; Savige J; Denison JC; Gregory MC; White JG; Barker DF; Greinacher A; Epstein CJ; Glucksman MJ; Martignetti JA
Am J Hum Genet; 2001 Nov; 69(5):1033-45. PubMed ID: 11590545
[TBL] [Abstract][Full Text] [Related]
7. Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation.
Eckly A; Strassel C; Freund M; Cazenave JP; Lanza F; Gachet C; Léon C
Blood; 2009 Apr; 113(14):3182-9. PubMed ID: 18984861
[TBL] [Abstract][Full Text] [Related]
8. Myosin-II repression favors pre/proplatelets but shear activation generates platelets and fails in macrothrombocytopenia.
Spinler KR; Shin JW; Lambert MP; Discher DE
Blood; 2015 Jan; 125(3):525-33. PubMed ID: 25395423
[TBL] [Abstract][Full Text] [Related]
9. The abnormal proplatelet formation in MYH9-related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition.
Chen Y; Boukour S; Milloud R; Favier R; Saposnik B; Schlegel N; Nurden A; Raslova H; Vainchenker W; Balland M; Nurden P; Debili N
J Thromb Haemost; 2013 Dec; 11(12):2163-75. PubMed ID: 24165359
[TBL] [Abstract][Full Text] [Related]
10.
Cechova S; Dong F; Chan F; Kelley MJ; Ruiz P; Le TH
J Am Soc Nephrol; 2018 Jan; 29(1):155-167. PubMed ID: 28993503
[TBL] [Abstract][Full Text] [Related]
11. Proplatelet formation deficit and megakaryocyte death contribute to thrombocytopenia in Myh9 knockout mice.
Eckly A; Rinckel JY; Laeuffer P; Cazenave JP; Lanza F; Gachet C; Léon C
J Thromb Haemost; 2010 Oct; 8(10):2243-51. PubMed ID: 20695978
[TBL] [Abstract][Full Text] [Related]
12. Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease.
Verver EJ; Topsakal V; Kunst HP; Huygen PL; Heller PG; Pujol-Moix N; Savoia A; Benazzo M; Fierro T; Grolman W; Gresele P; Pecci A
Ear Hear; 2016; 37(1):112-20. PubMed ID: 26226608
[TBL] [Abstract][Full Text] [Related]
13. Myosin IIA is critical for organelle distribution and F-actin organization in megakaryocytes and platelets.
Pertuy F; Eckly A; Weber J; Proamer F; Rinckel JY; Lanza F; Gachet C; Léon C
Blood; 2014 Feb; 123(8):1261-9. PubMed ID: 24243973
[TBL] [Abstract][Full Text] [Related]
14. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion.
Léon C; Eckly A; Hechler B; Aleil B; Freund M; Ravanat C; Jourdain M; Nonne C; Weber J; Tiedt R; Gratacap MP; Severin S; Cazenave JP; Lanza F; Skoda R; Gachet C
Blood; 2007 Nov; 110(9):3183-91. PubMed ID: 17664350
[TBL] [Abstract][Full Text] [Related]
15. Late onset and high-frequency dominant hearing loss in a family with MYH9 disorder.
Wasano K; Matsunaga T; Ogawa K; Kunishima S
Eur Arch Otorhinolaryngol; 2016 Nov; 273(11):3547-3552. PubMed ID: 26942920
[TBL] [Abstract][Full Text] [Related]
16. [Gene analysis and clinical features of MYH9-related disease].
Luo XJ; Cao K; Liu J; Duan QY; Chen SY; Zhang Y; Huang T; Mao XN; Li CG; Chen YS
Zhonghua Er Ke Za Zhi; 2021 Nov; 59(11):957-962. PubMed ID: 34711031
[No Abstract] [Full Text] [Related]
17. Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD.
Léon C; Evert K; Dombrowski F; Pertuy F; Eckly A; Laeuffer P; Gachet C; Greinacher A
Blood; 2012 Apr; 119(14):3333-41. PubMed ID: 22234693
[TBL] [Abstract][Full Text] [Related]
18. Targeted disruption of mouse ortholog of the human MYH9 responsible for macrothrombocytopenia with different organ involvement: hematological, nephrological, and otological studies of heterozygous KO mice.
Matsushita T; Hayashi H; Kunishima S; Hayashi M; Ikejiri M; Takeshita K; Yuzawa Y; Adachi T; Hirashima K; Sone M; Yamamoto K; Takagi A; Katsumi A; Kawai K; Nezu T; Takahashi M; Nakashima T; Naoe T; Kojima T; Saito H
Biochem Biophys Res Commun; 2004 Dec; 325(4):1163-71. PubMed ID: 15555549
[TBL] [Abstract][Full Text] [Related]
19. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes.
Arrondel C; Vodovar N; Knebelmann B; Grünfeld JP; Gubler MC; Antignac C; Heidet L
J Am Soc Nephrol; 2002 Jan; 13(1):65-74. PubMed ID: 11752022
[TBL] [Abstract][Full Text] [Related]
20. Defective VWF secretion due to expression of MYH9-RD E1841K mutant in endothelial cells disrupts hemostasis.
Cao Y; Sun Y; Deng Y; Wei G; Liu J; Jin S; Dong C; Kang X; Huo Y; Zhang J; Luo J
Blood Adv; 2022 Aug; 6(15):4537-4552. PubMed ID: 35764499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
